Purpose Triple-negative breast cancer (TNBC) accounts for approximately 20% of breast
cancer cases. Although there have been advances in the treatment of hormone receptor …

Improvements in outcomes for patients with resectable lung cancers have plateaued.
Clinical trials of resectable non-small-cell lung cancers with overall survival as the primary …

Purpose: While various studies have highlighted the prognostic significance of pathologic
complete response (pCR) after neoadjuvant chemotherapy (NAT), the impact of additional …

Background Recent data suggest that human epidermal growth factor receptor 2 (HER2)-
low breast cancer may represent a distinct entity. We aimed to compare disease …

Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical
assessment of the proportion of cells staining for the nuclear antigen Ki67 has become the …

Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in
approximately 30% of patients with triple-negative breast cancers (TNBC). In patients …

Abstract Programmed death 1 ligand 1 (PD-L1) is an immune regulatory molecule that limits
antitumor immune activity. Targeting of PD-L1 and other immune checkpoint proteins has …

Purpose Population studies have suggested that metformin use in diabetic patients
decreases cancer incidence and mortality. Metformin inhibits the growth of cancer cells in …

Triple-negative breast cancers are defined by a lack of expression of oestrogen,
progesterone, and ERBB2 receptors. This subgroup accounts for 15% of all types of breast …

Purpose To examine the association between beta-blocker (BB) intake, pathologic complete
response (pCR) rates, and survival outcomes in patients with breast cancer treated with …